How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
Portfolio Pulse from AJ Fabino
Shares of Pfizer Inc. (PFE) are trading near their 52-week low due to concerns over President Joe Biden’s Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs. However, Cantor Fitzgerald analyst Louise Chen believes the impact of the act on Pfizer's drugs will not be significant in the short term. She reiterated an Overweight rating on Pfizer with a $75 price target, indicating a potential 117.99% upside for the stock. Bristol-Myers Squibb Co (BMY) is also mentioned as they co-sell a drug with Pfizer that is on the negotiation list.
September 06, 2023 | 10:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol-Myers Squibb is mentioned as they co-sell a drug with Pfizer that is on the negotiation list for the Inflation Reduction Act.
Bristol-Myers Squibb is mentioned in the context of co-selling a drug with Pfizer that is on the negotiation list for the Inflation Reduction Act. This could potentially negatively impact the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Pfizer's stock is trading near its 52-week low due to concerns over the Inflation Reduction Act. However, an analyst sees a potential 117.99% upside, indicating a positive outlook.
The news directly mentions Pfizer and the potential impact of the Inflation Reduction Act on its stock price. However, the analyst's positive outlook and high price target suggest a potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100